Roche has secured CE mark for the Elecsys pTau217 blood test, developed alongside Eli Lilly, for detecting Alzheimer’s disease pathology.

The test is designed for measuring the phosphorylated Tau (pTau) 217 protein, a key indicator of amyloid pathology, often associated with Alzheimer’s.

The blood test uses standard thresholds to rule in or rule out amyloid pathology in individuals showing cognitive decline and is intended for application in both primary and secondary care settings.